Jane Street Group LLC Boosts Stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)

Jane Street Group LLC lifted its holdings in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 1,712.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 419,737 shares of the company’s stock after buying an additional 396,577 shares during the quarter. Jane Street Group LLC owned 0.73% of CNS Pharmaceuticals worth $51,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Geode Capital Management LLC boosted its position in CNS Pharmaceuticals by 90.5% during the fourth quarter. Geode Capital Management LLC now owns 387,064 shares of the company’s stock worth $47,000 after purchasing an additional 183,884 shares in the last quarter. XTX Topco Ltd purchased a new stake in CNS Pharmaceuticals during the fourth quarter worth $36,000. Integrated Wealth Concepts LLC purchased a new stake in CNS Pharmaceuticals during the fourth quarter worth $30,000. Finally, Wealthfront Advisers LLC purchased a new stake in CNS Pharmaceuticals during the fourth quarter worth $26,000. 14.02% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on CNSP shares. Alliance Global Partners reiterated a “buy” rating on shares of CNS Pharmaceuticals in a research report on Thursday, May 22nd. Maxim Group reissued a “hold” rating on shares of CNS Pharmaceuticals in a report on Tuesday, March 25th.

CNS Pharmaceuticals Stock Down 1.0%

NASDAQ CNSP opened at $1.03 on Tuesday. CNS Pharmaceuticals, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $414.00. The stock has a market cap of $5.63 million, a price-to-earnings ratio of -0.01 and a beta of 2.65. The business has a fifty day moving average of $1.09 and a 200-day moving average of $3.32.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its quarterly earnings results on Thursday, May 15th. The company reported ($1.58) earnings per share for the quarter.

CNS Pharmaceuticals Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.